The Calamos Phineus Long/Short Fund (Class I shares at NAV) declined -1.32% in Q4 on an average net equity exposure of 16.6%.
The biotechnology company, which develops genetically engineered silkworms, says it is moving toward commercial production of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results